News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
TDxd for treating HER2-positive breast cancer with brain and/or leptomeningeal metastases
Aug 17, 2024, 14:04

TDxd for treating HER2-positive breast cancer with brain and/or leptomeningeal metastases

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X about recent paper by Takahiro Nakayama et al., titled “Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)” published on Breast Cancer.

Authors: Takahiro Nakayama, Naoki Niikura, Takashi Yamanaka, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Hironori Nomura, Shosuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Nobuhiro Shibata, Akihiko Shimomura, Yuri Ozaki, Shuji Sakai, Daisuke Takiguchi, Takehiko Takata, Armin Bastanfard, Kazuhito Shiosakai, Junji Tsurutani

Image

“ Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) | Breast Cancer.”

Source: Elisabetta Bonzano/X

Akihiko Shimomura Armin Bastanfard Breast Cancer cancer Daisuke Takiguchi Elisabetta Bonzano HER2 positive breast cancer Hironori Nomura IRCCS San Matteo Polyclinic Foundation Junji Tsurutani Kazuhito Shiosakai Kazuo Matsuura Kenichi Inoue leptomeningeal metastases Miki Yamaguchi Mitsugu Yamamoto Naoki Niikura Nobuhiro Shibata OncoDaily Oncology Sachiko Takahara Shosuke Kita Shuji Sakai Takahiro Nakayama Takashi Yamanaka Takehiko Takata Tomoyuki Aruga Trastuzumab deruxtecan Yuri Ozaki
Special Coverage
Blog
Dec 30, 2024, 19:52
CelloType: A New Machine Learning Tool for Analyzing Cancer Cells and Tissues
Blog
Dec 30, 2024, 19:26
“QI Scholar Nursing Presentations Part 2” from the SIOP Nursing Network
Science
Dec 30, 2024, 13:52
Nico Gagelmann: Selected clinical studies 2024 in hematology
Insight
Dec 30, 2024, 13:43
Roupen Odabashian: When it comes to real-life cases, physicians still outperform AI
Blog
Dec 30, 2024, 13:42
Shaban Juma: The key to being one step ahead in the fight against cancer
Positive
Dec 30, 2024, 13:42
Improving the lives of children with cancer everywhere - St. Jude Children's Research Hospital
Blog
Dec 30, 2024, 13:37
Matthew Pech: The failure of ex vivo gene therapy for sickle cell and the role of the TPP in the drug development process
Insight
Dec 30, 2024, 13:35
James Crowley: Elevated expression of CCR7 is generally indicative of poor prognosis in cancers
Insight
Dec 30, 2024, 13:30
Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer
Blog
Dec 30, 2024, 13:25
Sanjay Popat: Wouldn’t it be great if FDA Oncology approvals were mutually approvable by MHRA?
Insight
Dec 30, 2024, 13:23
Satya Prakash Yadav: 2024 blockbuster Menin inhibitor for infant ALL
Insight
Dec 30, 2024, 13:10
Promising response to lurbinectedin in NUT carcinoma by M.V. Sánchez Becerra et al. - Vivek Subbiah